FDA approves new drug to treat multiple sclerosis | Siponimod versus placebo in secondary progressive multiple sclerosis EXPAND : A double-blind, randomised, phase 3 study |
---|---|
Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis |
Marin Collazo IV expert opinion | Network of Pediatric MS Centers |
---|---|
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes | Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis |
Pathogenesis and epidemiology of multiple sclerosis.